Login to Your Account

In The Clinic NEWS
DUBLIN – Further information on the first death of a cancer patient undergoing oncolytic viral therapy with a vesicular stomatitis virus (VSV) strain engineered to express human interferon-β (IFN-β) has emerged.

LONDON – A phase IIb placebo-controlled trial reported in The Lancet is the first to show clinical efficacy of a gene therapy in the treatment of cystic fibrosis.


Cerespir Inc. submitted a special protocol assessment (SPA) plan for the phase III trial with CSP-1103 to treat mild cognitive impairment (MCI) Alzheimer's disease (AD) – "the right drug at the right time," CEO Daniel Chain told BioWorld Today.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: